Home / Compounded GLP-1 / Compounded GLP-1 safety: what the adverse-event data shows
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
Compounded GLP-1 safety: what the adverse-event data shows
Quick answer
Compounded GLP-1 drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before marketing. As of February 28, 2025 the FDA had logged more than 455 adverse-event reports for compounded semaglutide and more than 320 for compounded tirzepatide. The single most common failure is a dosing error — and it is a failure mode the brand devices do not have.
The $449 tier has a condition. LillyDirect prices Zepbound at $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) a month under its self-pay programme. The $449 rate on 7.5 mg and above holds only if you refill within 45 days of your previous delivery. Miss that window and the refill is charged at the standard rate — reported at $499 to $699 depending on dose — before the programme rate resumes on the next order. Re-read at source 4 August 2026.
The reported harms
Reported harms — FDA adverse-event dataAs of February 28, 2025, the FDA had received more than 455 adverse-event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide. A recurring cause is dosing error: patients or clinicians measuring the wrong volume from a multi-dose vial, sometimes by a factor of ten. Brand auto-injectors and single-dose vials remove that failure mode; a compounded multi-dose vial reintroduces it.
Why dosing errors happen with compounded vials
A brand pen or single-dose vial delivers a fixed, pre-measured dose. A compounded multi-dose vial requires the patient (or a clinician) to draw the correct volume with a syringe. The FDA has documented cases of patients and clinicians miscalculating by as much as a factor of ten, some requiring hospitalisation.
This is the clearest concrete safety difference between the two products, and it has nothing to do with the molecule — it is the delivery format.
Semaglutide salts are not semaglutide
Semaglutide salts are not semaglutideSome compounded products use semaglutide salts — semaglutide sodium or semaglutide acetate. These are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has stated they are not approved for use in compounding. A program that will not state its exact salt form and concentration cannot be evaluated on safety.
What separates a legitimate programme
A verifiable pharmacy licence, a named prescriber, a disclosed salt form and concentration, and no 'research use only' language. A programme that will not tell you its exact formulation cannot be assessed on safety, and should be treated accordingly.
The comparison that actually matters now
The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of October 15, 2026, brand Zepbound is $299–$449 through LillyDirect, the Wegovy pen is $349 and the Wegovy pill $149 at its 1.5 mg starting dose ($299 at maintenance doses) through NovoCare, and commercial coverage with a savings card can bring brand costs to about $25. Compounded programs in our index charge $99–$399 at their lowest standing price.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
Brand vs compounded — monthly cost, read October 15, 2026
Brand prices are read from NovoCare and Lilly; compounded prices from each program’s own page. Compounded drugs are not FDA-approved. The Wegovy list price is NovoCare’s $1,349.02 per package.
Frequently asked questions
Are compounded GLP-1 drugs safe?
They are not FDA-verified for safety, effectiveness or quality. The FDA has received 455+ adverse-event reports for compounded semaglutide and 320+ for compounded tirzepatide, with dosing errors a recurring cause. Risk depends heavily on the pharmacy and the delivery format.
What is the biggest safety risk?
Dosing error from self-measured multi-dose vials. Brand pens and single-dose vials remove this failure mode entirely.
What are semaglutide salts?
Semaglutide sodium and semaglutide acetate are salt forms that are not the same active ingredient as the semaglutide base in Wegovy and Ozempic. The FDA has stated they are not appropriate for compounding.
How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.